FTRE: יחס מחיר למכירות Fortrea Corp

סמל מסחרי של Fortrea Corp (FTRE)

The price-to-sales ratio for Fortrea Holdings Inc. (FTRE) exhibits a downward trend as the consolidated CRO market faces pressure from AI technologies. The metric stands at 0.70, reflecting the global scale of early-phase research trials. However, a decline in biotech investment has weakened the pricing power of Fortrea Holdings Inc. (FTRE), forcing the company to offer discounts to ensure full capacity utilization of its laboratories.

FTRE יחס מחיר להכנסות fortrea.com (12.03.2024 - 17.11.2026)

פילוחי מדדים ואנליטיקה של חברת Fortrea Holdings Inc. (FTRE)

- מחיר ותחזית קונצנזוס למחירים:
ניתוח כללי של החברה:FTRE - Fortrea
פריט של המותג Fortrea Clinical

Fortrea Holdings Inc. generates revenue by providing specialized CRO drug testing services for the biopharmaceutical sector. The ratio of the business's market value to annual turnover, as reflected by the historical P/S, measures the model's ability to withstand industry shocks and technological pressure. It is critical for investors to benchmark this ratio against US market averages to identify overvaluation risks or signs of asset stagnation.